✦ LIBER ✦

Acalculous cholecystitis during the course of acute Epstein–Barr virus infection

✍ Scribed by Evangelos Cholongitas; Konstadinos Katsogridakis; Maria Dasenaki

Book ID: 118450486
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 99 KB
Volume: 13
Category: Article
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2008.06.031

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acalculous cholecystitis during the cour

Acalculous cholecystitis during the course of acute Epstein–Barr virus infection and Gilbert's syndrome

✍ Chiara Iaria; Maria Silvana Leonardi; Carmelo Fabiano; Antonio Cascio 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Acute acalculous cholecystitis during th

Acute acalculous cholecystitis during the course of primary Epstein–Barr virus infection: a new case and a review of the literature

✍ Chiara Iaria; Lucia Arena; Giovanni Di Maio; Maria Grazia Fracassi; Maria Silvan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Acute Acalculous Cholecystitis Caused by

Acute Acalculous Cholecystitis Caused by Epstein-Barr Virus Infection

✍ Joe Dylewski 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Acute acalculous cholecystitis as the in

Acute acalculous cholecystitis as the initial presentation of primary Epstein-Barr virus infection

✍ Alexia Prassouli; John Panagiotou; Marina Vakaki; Irene Giannatou; Achilleas Ati 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Epstein-Barr Virus Infectious Mononucleo

Epstein-Barr Virus Infectious Mononucleosis Associated with Acute Acalculous Cholecystitis

✍ E. Lagona; F. Sharifi; A. Voutsioti; A. Mavri; M. Markouri; A. Attilakos 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 286 KB

Cholestatic hepatitis, acute acalculous

Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein–Barr virus infection under azathioprine

✍ Stefan Hagel; Tony Bruns; Marcus Kantowski; Peter Fix; Thomas Seidel; Andreas St 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

The use of immunomodulators for the treatment of inflammatory bowel disease (IBD) is increasing. One of the most common adverse effects associated with this kind of therapy is infectious complications. In recent years, special attention has been paid to certain latent infections which in patients un